Nemolizumab for Eczema
(NemoBaby Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The primary objective of the study is to assess the pharmacokinetics (PK) and safety of nemolizumab in pediatric participants (aged 6-23 months) with moderate-to-severe atopic dermatitis (AD) who are not adequately controlled with topical treatments.
Are You a Good Fit for This Trial?
This trial is for infants and toddlers aged 6 to 23 months with moderate-to-severe eczema that hasn't improved enough with creams or ointments. Children must have a certain level of skin involvement, and their caregivers need to agree to the study requirements.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Nemolizumab
Trial Overview
The study is testing nemolizumab, an injectable medication, in young children with moderate-to-severe eczema who haven't responded well to topical treatments. The main focus is on how the drug moves through the body and its safety.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants aged 6 to 23 months will receive a subcutaneous (SC) loading dose of nemolizumab high dose on Baseline/Day 1 followed by nemolizumab low dose SC once every 4 weeks (Q4W) for up to 52 weeks (last dose at 48 weeks).
Find a Clinic Near You
Who Is Running the Clinical Trial?
Galderma R&D
Lead Sponsor
Flemming Ørnskov
Galderma R&D
Chief Executive Officer since 2019
MD, MPH
Baldo Scassellati Sforzolini
Galderma R&D
Chief Medical Officer
MD, PhD
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.